FOLFIRINOX in Patients With Inoperable Pancreatic Cancer

NCT01359007 | Terminated Phase 2 Results

• 1 other identifier: 1977
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

The prognosis of patients with locally advanced unresectable pancreatic cancer is poor, and the median survival is less than 1 year. FOLFIRINOX therapy, which induces tumor downstaging sufficient to allow surgical resection, could improve the overall survival of patients with locally advanced pancreatic cancer. Based on the FOLFIRINOX regimen for advanced pancreatic cancer, a phase II study of this regimen in patients with locally advanced unresectable and borderline pancreatic cancer is planned to determine the rate of conversion to operability.

Conditions

Adenocarcinoma of Pancreas

Keywords

Locally advanced unresectable adenocarcinoma of pancreas; Borderline resectable adenocarcinoma of pancreas

Outcome Measures

Primary Outcomes (1)

• To Estimate, Among Patients With Locally Advanced Unresectable and Borderline Resectable Pancreatic Cancer, the Proportion in Whom R0 Resection is Achieved After Neoadjuvant Therapy.

  2 years

Secondary Outcomes (4)

• Proportion of Patients Whose Pancreatic Cancer is Operable (Resulting in R0 or R1 Resection) Following Induction Therapy.

  2 years

• Response Rate (Either Complete Response (CR) or Partial Response (PR) by RECIST 1.1 Criteria)

  2 years

• Overall Survival

  2 years

• Number of Participants Who Experienced Toxicity

  2 years

Study Arms (1)

FOLFIRINOX

EXPERIMENTAL

Combination of drugs (Irinotecan, Oxaliplatin, Leucovorin, and 5-Fluorouracil (5-FU)) known as FOLFIRINOX every 2 weeks for 4 treatments. At the end of 4 cycles, patients will be re-evaluated for resectability by CT scan within 28 days of the last dose of chemo. If found amendable to surgery, patient will proceed with resection, and type of resection (R0 or R1) will be recorded.

Drug: Irinotecan, Oxaliplatin, Leucovorin, 5-FU

Interventions

Irinotecan, Oxaliplatin, Leucovorin, 5-FU DRUG

5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently

FOLFIRINOX

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically or cytologically confirmed locally advanced unresectable or borderline resectable adenocarcinoma of pancreas
• Patients must have measurable disease as defined by RECIST 1.1 RECIST evaluations must have occurred within 4 weeks prior to study entry
• No evidence of hepatic or pulmonary metastatic disease by CT or CT/PET scans
• Male or non-pregnant and non-lactating female age \> or equal to 18 years and \< or equal to 70 years of age
• Patient must have received no prior therapy for the treatment of locally advanced unresectable or borderline resectable pancreatic cancer
• Patients must have adequate blood counts at baseline and blood chemistry levels
• Patient has ECOG Performance Status 0 to 1

You may not qualify if:

• Patients with islet cell neoplasms excluded
• Patients with known brain metastases
• Therapeutic Coumadin for a history of pulmonary emboli or deep vein thrombosis (DVT)
• Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
• Known infection with HIV, hepatitis B or hepatitis C
• Major surgery or vascular device placement within 4 weeks prior to Day 1 of treatment in study
• Prior chemotherapy or radiation for pancreatic cancer
• History of allergy or hypersensitivity to the study drugs
• Patient is enrolled in any other clinical protocol or investigational trial
• Metastatic disease on radiological staging
• Prior malignancy within last 3 years
• Significant cardiac disease
• Any prior gastrointestinal (GI) disease or history of prior pelvic or abdominal radiation in which in opinion of the investigator may place the patient at increased risk
• peripheral sensory neuropathy \> or equal to grade 2 at baseline

Sponsors & Collaborators

• University of Oklahoma: lead

Study Sites (1)

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

Location

MeSH Terms

Interventions

Irinotecan; Oxaliplatin; Leucovorin; Fluorouracil

Intervention Hierarchy (Ancestors)

Camptothecin; Alkaloids; Heterocyclic Compounds; Coordination Complexes; Organic Chemicals; Formyltetrahydrofolates; Tetrahydrofolates; Folic Acid; Pterins; Pteridines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Coenzymes; Enzymes and Coenzymes; Uracil; Pyrimidinones; Pyrimidines; Heterocyclic Compounds, 1-Ring

Results Point of Contact

• Title: Ingrid Block - CTO Directo
• Organization: University of Oklahoma

ingrid-block@ouhsc.edu

405-271-8777

Study Officials

• Shubham Pant, MD

  University of Oklahoma

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 23, 2011
• First Posted: May 24, 2011
• Study Start: May 1, 2011
• Primary Completion: October 1, 2013
• Study Completion: October 1, 2013
• Last Updated: March 9, 2018
• Results First Posted: March 9, 2018

Record last verified: 2018-02

Locations

US (1)